新規SERM「バゼドキシフェン」の長期にわたる有効性と安全性～最新の5年間投与試験の論文より～

「Silverman SL, Chines AA, Kendler DL, et al: Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23: 351-363, 2012」「de Villiers TJ, Chines AA, Palacios S, et al: Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 22: 567-576, 2011」バゼドキシフェンは新規のSERMと分類され, 閉経後骨粗鬆症治療の有力な選択肢のひとつとして国内外ともに期待されている.